Chimeric Therapeutics Ltd (ASX:CHM) non-executive director George Matcham has demonstrated his confidence in the company’s cell therapy strategy with the purchase of shares in an on-market transaction.
Matcham purchased a total of 500,000 shares in a direct interest on August 2, marking his first share purchase.
Advisory board appointment
The company recently appointed Dr Yi Lin as the inaugural member of its newly established Cellular Immunotherapy Scientific Advisory Board (CI-SAB).
A new cellular immunotherapy scientific advisory board was established to gain expert guidance on the development of its growing pipeline.
Chimeric Therapeutics is presently in phase one clinical trial for its CHM 1101 asset, a novel CAR-T therapy for the treatment of patients with Glioblastoma.